Fda accepts biologics license applications for exagamglogene autotemcel (exa-cel) for severe sickle cell disease and transfusion-dependent beta thalassemia

Boston & zug, switzerland--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) and crispr therapeutics (nasdaq: crsp) today announced that the u.s. food and drug administration (fda) has accepted the biologics license applications (blas) for the investigational treatment exagamglogene autotemcel (exa-cel) for severe sickle cell disease (scd) and transfusion-dependent beta thalassemia (tdt). the fda has granted priority review for scd and standard review for tdt and assigned pres.
VRTX Ratings Summary
VRTX Quant Ranking